Contraception in Adolescents by Greydanus, Donald E. et al.
University of Kentucky
UKnowledge
Pediatrics Faculty Publications Pediatrics
2012
Contraception in Adolescents
Donald E. Greydanus
Michigan State University
Carolyn M. Lentzsch-Parcells
University of Kentucky
Hatim A. Omar
University of Kentucky, hatim.omar@uky.edu
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/pediatrics_facpub
Part of the Diseases Commons, Gender and Sexuality Commons, Obstetrics and Gynecology
Commons, and the Pediatrics Commons
This Book Chapter is brought to you for free and open access by the Pediatrics at UKnowledge. It has been accepted for inclusion in Pediatrics Faculty
Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Repository Citation
Greydanus, Donald E.; Lentzsch-Parcells, Carolyn M.; and Omar, Hatim A., "Contraception in Adolescents" (2012). Pediatrics Faculty
Publications. 100.
https://uknowledge.uky.edu/pediatrics_facpub/100
Contraception in Adolescents
Notes/Citation Information
Published in Adolescent Medicine: Pharmacotherapeutics in General, Mental and Sexual Health. Donald E.
Greydanus, Dilip R. Patel, Hatim A. Omar, Cynthia Feucht, & Joav Merrick, (Eds.). p. 361-385.
© 2012 Walter de Greyter GmbH & Co. KG, Berlin, Boston
The copyright holder has granted permission for posting the chapter here.
Reprinted as an article in International Journal of Child and Adolescent Health, v. 5, no. 4, p. 403-419.
Reprinted as a book chapter in Child and Adolescent Health Yearbook 2012. Joav Merrick, (Ed.). p. 473-494.
This book chapter is available at UKnowledge: https://uknowledge.uky.edu/pediatrics_facpub/100
19 Contraception in adolescents 
Donald E. Creydanus, Carolyn M. Lentzsch-Parcells, 
and Hatim A. Omar 
The age of adolescence is the time when most adolescents in the world begin to be sex-
ually active with resultant millions of pregnancies and sexually transmitted diseases 
(STDs). This chapter considers methods of contraception for these adolescents, includ-
ing oral contraceptives, transdermal contraception, minipills, intravaginal ring, inject-
able contraception, intrauterine devices (IUDs), barrier contraceptives, implants, and 
others. It is important for clinicians caring for sexually active youth to provide information 
regarding contraception and appropriate contraceptive prescriptions. 
19.1 Introduction 
The median age of first intercourse in the United States, Western Europe, Eastern 
Europe (Ukraine), Eurasia (Russia), and other parts in the world is 16 years of age, 
with many youth having multiple sexual partners. Clinicians caring for adolescents 
should ask about possible coital behavior and provide effective contraception to 
those youth continuing to be sexually active without intent of becoming pregnant 
(1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23). The following box lists 
questions helpful to ask when discussing contraception with adolescents - particularly 
if they are sexually active. 
A number of effective and safe contraceptive methods (see ~Tab. 19.1) are avail-
able for the sexually active adolescent who wishes to avoid pregnancy. The most 
effective methods of contraception include abstinence, combined oral contraceptives 
(24), transdermal contraceptive patch (Ortho Evra®), vaginal contraceptive rings 
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Tab. 19.1: Contraceptive methods. 
Abstinence 
Rhythm method of contraception (periodic abstinence) 
• Calendar 
• Ovulation method 
• Symptothermal 
• Postovulati on 
Oral contraceptives (combined) 
Transdermal contraceptive patch (Ortho Evra) 
Vaginal contraceptive ring (NuvaRing) 
Minipills (progestin-only pills [POPs]) 
Emergency contraceptives (ECs) 
Vaginal barrier contraceptives 
• Diaphragm 
• Vaginal contraceptive sponge 
• Cervical cap (Prentif Cavity-rim®) 
• Female condom (Reality®) 
• Vaginal spermicides 
• Male condoms 
Injectable Contraceptives 
• Depo-Provera® 
• Lunelle® 
IUDs 
• Progestasert® IUD (with progesterone) 
• ParaGard® (Copper T380A IUD) 
• Mirena® (IUD with levonorgestrel) 
Implants 
• lmplanon 
• Norplant (no longer available in the United States) 
Sterili zation 
• Female 
• Male (vasectomy) 
Coitus interruptus 
(NuvaRing®), progestin-releasing implant (lmplanon®), IUDs, and intramuscular 
depo-medroxy-progesterone acetate (Depo-Provera, DMPA); these methods have 
pregnancy rates under 1/100 woman-years of use (see ~Tab. 19.2). Unfortunately, 
the difference in contraceptive effectiveness between perfect use and typical use 
leads to millions of unintended pregnancies each year. Perfect use is defined as cor-
rect, consistent, and continued use of a method chosen by the sexually active patient. 
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Tab. 19.2: Effectiveness of methods. 
Method Perfect Use Typical Use 
OCP >99% 95% 
Ortho Evra >99% 98%- 99% 
NuvaRing 98%-99% 98%- 99% 
DMPA 99.7% 99.7% 
Mirena 99.9% 99.9% 
ParaGard 99.4% 99.2% 
Condoms 97% 86% 
lmplanon >99% 100%* 
*Postmarketing Pearl index of 0.024. 
The less patient-dependent a method, the closer the typical usage is to the perfect 
usage. Thus, methods such as the implant, DMPA, and IUDs have typical usage 
that is virtually equal to perfect usage, and the intravaginal ring and transdermal 
patch have better typical usage than oral contraceptive pills (OCPs). The barrier meth-
ods (condoms, diaphragms, cervical caps, vaginal sponges, female condoms, and va-
ginal spermicides) are not typically recommended as the only method for adolescents, 
unl ess they are mature and motivated enough to use them; even then, pregnancy rates 
are higher than with the methods ide ntified above as the most effective ones. 
Over the past 20 years, a number of newer contraceptive methods have bee n ap-
proved in the United States by the U.S. Federal Drug Administration; these include 
ECs (Preven®, Plan B®), Depo-Provera®, the cervical cap, Lune lle® (injectable contra-
ceptive with estrogen), Mire na® (an IUD with levonorgestrel), the contraceptive patch 
(Ortho Evra®), and an intravaginal ring(NuvaRing®) . Over the past 15 years, research 
has developed various ways of contraceptive steroid release (see the following box, 
"Methods to Deliver Steroids"), producing a number of potential advantages (see the 
following box, "Advantages of Newer Contraceptive Methods") . After OCPs were 
developed in the 1960s, the emphasis has been on having pill formulations that have 
reduced estrogen and progestin dosages along with the deve lopment of phasic and ex-
tended dosing regimens as well as the above-mentioned newer methods. This chapter 
reviews some of these important methods of contraception . .,.Fig. 19.1 lists frequency 
of contraceptive use by sexually active adolescents in the United States. 
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Fig. 19.1: Contraceptive use among never-married femal e adolescents 15-19 years of age who 
have had sexual intercourse in the past 3 months, by specified method used at last intercourse and 
race and Hispanic origin : United States, 2002. 
19.2 Oral contraceptives (OCPs; combined oral contraceptives [COCs]) 
One of the main contraceptives for several decades has been the COC, containing syn-
thetic estrogen (usually ethinyl estradiol [EEL occasionally mestranol) and synthetic 
progesterone (several types, see the following box) (1,2,3,4,5,6,7). 
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The mechanisms of the combined birth control pill (OCPs or COCs) include preg-
nancy prevention by inhibition of ovulation, cervical mucus thickening, endometrial 
atrophy, and tubal transport changes. When discussing OCPs with adolescents, it is 
helpful to note the many benefits and uses of these pills, as listed in the following 
box. OCPs are usually available as 28-day packs, which contain 21 days of active 
pills containing consistent steroid dosages (monophasic) and placebo pills for the last 
7 days to allow the adolescent to continue with one pill a day. Variations on this are 
being developed, such as having only 2 days of placebo for each 28-day cycle or 
extended cycles. 
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Multiphasic pills have also been developed that contain steroid dosages that vary · 
through the month (bi- or triphasic). There is no evidence that multiphasic pills provide 
any benefit over monophasic formulations and are often more expensive. There is also 
no evidence that one OCP brand is better than another, only that an individual adoles-
cent may prefer or tolerate one brand over another. Generally, a pill with between 
20 meg and 35 meg of EE is selected. While efficacy appears to be the same, pills con-
taining 20 meg or less of EE have been shown to have a greater rate of irregular bleeding 
than higher dose pills. 
Some females benefit from extending the menstrual cycle to reduce the number of 
yearly menstrual periods. This can be applied to those having problems worsened by 
their menstrual periods, such as some with epilepsy, headaches, menorrhagia, pre-
menstrual tension syndrome (PTS), iron deficiency anemia, endometriosis, coagulation 
disorders; those receiving anticoagulation; athletes wishing to avoid a cycle during an 
important sports event; and others. Some 91-day packs are currently commercially 
available (Seasonique®, Seasonale®, LoSeasonique®). 
OCPs may be initiated according to three different schedules. First, for the Quick 
Start, the patient should take the first pill immediately, and backup contraception 
should be used for 7 days (24) . Urine pregnancy test may be performed if patient has 
had unprotected sex since last menses and should be repeated if next menses is missed 
or there are other concerns for pregnancy. Emergency contraception may be consid-
ered if unprotected sex has occurred in the last 5 days. Quick Start may improve com-
pli ance, decrease confusion, and provide immediate contraception. OCPs can also be 
started on the first day of the next menses, and no backup method is needed. Lastly, 
they may be started on the Sunday after the next menses. This may cause confusion, 
difficulty with weekend refills, and delay in initiation, especially in women with irreg-
ular menses. ~Tab. 19.3 provides instruction on management of missed pills. The sex-
ually active adolescent should be instructed that OCPs (COCs) do not prevent STDs, 
and thus, condoms, are also recommended. 
Tab. 19.3: Missed OCPs. 
EE Dosage of Pill Number of Pills Missed 
30-35 meg 1- 2 pills missed: 
Take last missed pill immediately 
and continue normal pill-taking 
schedule. 
Backup method not needed. 
20 meg or less 1 pill missed: 
Take last missed pill immediately 
and continue normal pill-taking 
schedule. 
Backup method not needed. 
3 or more pill s missed*: 
Take last missed pill immediately and 
continue normal pill-taking schedule. 
Discard other missed pills. 
Backup method needed for 7 days. 
Consider EC. 
2 or more pills missed*: 
Take last missed pill immediately and 
continue normal pill-taking schedule. 
Discard other missed pills. 
Backup method needed for 7 days. 
Consider EC. 
*If missed pills occur during third week, finish active pills, discard placebos, and start new pack. 
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19.2.1 Contraindications to OCPs/COCs 
Counseling sexually active youth about OCPs involves discussing conditions that may 
present increased risks for the adolescent. The World Health Organization (WHO) 
has published guidelines for medical eligibility to help in this endeavor (~Tab. 19.4). 
Females in WHO Category 1 do not have any restrictions to using OCPs, while\those 
in WHO Category 2 have some increased medical risk . However, OCPs and other com-
bined hormonal contraceptives should still be considered for those in Category 2 as the 
risk of pregnancy may outweigh the medica l concerns. Females in WHO Category 3 
have such an increased risk that they are not placed on OCPs unless there is no other 
available, effective contraceptive agent. Finally, those in WHO Category 4 are not placed 
on the OCP because the medical risks are too great. 
Tab. 19.4: WHO medical eligibility categori es for OCPs. 
Category 1 (No Restrictions) 
• Antibiotics 
• Benign breast disease 
• Benign ovarian tumors 
• Cervical ectropion 
• Dysmenorrhea 
• Endometriosis 
• Epilepsy 
• Family history of breast cancer 
• Gestational trophoblastic disease (benign or malignant) 
• Headaches (mild) 
• History of ectopic pregnancy or abortion (post abortion after first or second trimester) 
• History of gestational diabetes 
• Increased STD ri sk 
• Iron deficiency anemia 
• Irregular menstrual bleeding 
• Obesity 
• Ovarian or endometrial cancer 
• Past pelvic surgery 
• Pelvic inflammatory disease (PID) 
• Postpartum at or over 21 days 
• Thyroid disorders (as hypo/hyperthyroidi sm, simple go iter) 
• Varicose veins 
• Various infections: malaria, tuberculosis, others 
• Viral hepatitis carri er 
Category 2 (Caution) 
• Cervical cancer 
• Diabetes mellitus (uncomplicated) 
(Continued) 
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Tab. 19.4: WHO medical eligibility categories for OCPs. (Continued) 
• Headaches (severe and if they start after beginning OCPs) 
• Hypertension at 140-159/1 00-1 09 mm Hg 
• Major surgery without prolonged immobilization 
• Migraine headaches without focal neurologic involvement. 
• Patients who have a hard time taking the OCP correctly: 
Drug or alcohol abuse 
Mental retardation 
Persistent history as poor OCP takers 
Severe psychiatric disorders 
• Sickle-cell disease or sickle-C disease 
• Undiagnosed breast mass 
Category 3 (Usually No OCP Given) 
• Gallbladder disease 
• Lactating (6 weeks to 6 months) 
• Less than 21 days postpartum 
• Medications that interfere with OCP efficacy 
• Undiagnosed abnormal vaginal/uterine bleeding 
Category 4 (OCP Contraindicated) 
• Breast cancer 
• Cerebrovascular accident (active or history) 
• Complicated structural heart disease (with pulmonary hypertension, atrial fibrillation, or history 
of subacute bacterial endocarditis) 
• Coronary (or ischemic) heart disease (active or history) 
• Deep vein thrombosis or pulmonary embolism (active of history) 
• Diabetes mellitus (complicated with retinopathy, neuropathy, nephropathy) 
• Headaches (including migraine headaches) with focal neurologic symptoms 
• Hypertension (severe: 160+/11 0+ mm Hg or with vascular complications) 
• Lactation under 6 weeks 
• Liver disease (including liver cancer, benign hepatic adenoma, active viral hepatitis, severe 
cirrhosis) 
• Pregnancy, complicated 
• Surgery (involving the lower extremities and/or prolonged immobilization 
Used with permission from: Greydanus DE. Contraception. In: Greydanus DE, Patel DR, Pratt H, 
Bhave S, eds. Course manual for adolescent health. New Delhi, India: New United Process, 
Naraina Industrial Area, 2002:309-24. 
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19.2.2 Cardiovascular risks and OCPs 
If the adolescent has had a venous thrombosis (VT) in the past, OCPs are contraindi-
cated (25-27). VT risks are greater in the adolescent and young adult female than 
risks for arterial thrombosis. Morbid obesity is a well-known risk factor for VT, 
though the amount of increased risk in the otherwise healthy adolescent is not 
known. Most adolescents who develop a VT do not have identifiable risk factors. 
Screening questions for adolescents seeking OCPs in regards to VT are listed in the 
following box. 
The following box lists risk factors for thrombosis. Death from cardiovascular dis-
ease (arterial and venous) can occur among 20- to 24-year-old females at 2-6 per 
million per year. Thus, death from the OCP is a small, but known risk, though the 
risk of death from pregnancy is much greater (1 0,25). The OCP should be stopped 
if the adolescent has a condition requiring prolonged bed rest, as with major surgery. 
Smoking should be discouraged in the adolescent but is not a reason by itself to 
avoid OCPs. Blood pressure can increase in those on OCPs and should be moni-
tored. If there is a personal or family history for increased lipids, the OCP is permitted 
if the low density lipoprotein range is under 160 mg/dl or the triglycerides under 250. 
Other guidelines may be used by the clinician if these guidelines are not accepted in 
one's region. 
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19.2.3 OCPs and miscellaneous risks 
The re are a number of so-called "minor" adverse effects that are well-known with the 
OCPs, such as headaches, mood c hanges, nausea, and breast tenderness. These effects 
are usually tolerated and do disappear with cessation of the pill. Though ofte n linked to 
OCPs, there is no clear evidence that weight ga in is the directly caused by OCP/COC 
use. Uterine breakthrough bleeding can be seen with OCPs and is a common cause for 
stopping the O CPs. Breakthrough bleeding usua lly resolves with continued use ofthe 
same OCP. O ccas ionally, a change to anothe r brand is necessary. If the breakthro ugh 
bleeding is significant, the patient should be eva luated for other causes. 
Adolescents with well-contro ll ed diabetes me llitus usually do well with low dose 
OCPs; OCPs are not provided if complications arise, such as hype rtension, retinopathy, 
nephropathy, or neuropathy. Some clinicians recommend that OCPs be avoided in 
those with migraine headac hes hav ing auras and in those with worsening headaches 
on the OCP. Some anticonvulsants lead to reduced OCP efficacy. These include barbi-
turates, phenytoin, carbamazepine, fe lbamate, topiramate, and vigabatrin. A number of 
other medications can interfere with OCP efficacy, such as rifampin, griseofu lvin, ke-
toconazole, itraconazole, and others. Antacids and OCPs should be separated by at 
least 3 hours . Those with active liver disease should avoid OCPs. 
19.3 Transdermal hormonal contraception 
The use of the patch to provide contraception has become a popular method for many ado-
lescents and is based on decades-long research in using in transdermal mechanisms to 
de liver medication. Patients should be advised that the same adverse effects as OCPs 
apply, with the poss ible addition of increased breast symptoms and local dermatitis at the 
patch site. The contraceptive patch is about the size of a matchbook and placed on the 
skin in various sites: upper outer arm, buttocks, upper torso, and abdomen. It is not placed 
on the breasts or skin that is irritated or cut. The patch produces a daily release of 20 meg EE 
and 150 meg of norelgestromin, a hormone that is the active metabolite of norgesti mate. The 
patch is typically started on the first menstrual day, replaced weekly for 3 weeks, and then 
no patch is placed on week 4, a llowing menses to occur. A Quick Start, as discussed 
above, may also be used for initiation. A different site is chosen with each patch application. 
Pregnancy rates are similar to the OCPs, 0.7 to 1.24 per 100 woman-years with the 
patch versus 2.1 8 for OCPs (1 0). This rate is not affected by exposure to water baths or 
saunas, strenuous exercise, or warm, humid climates. Increased risks for pregnancy 
include wearing a patch for more than 7 days, patch detachment, and not placing a 
patch after being off for 7 days. If the patch detaches, it should be reattac hed immedi-
ately . If the patch cannot be reattached with its own adhesive, a new patch should be 
placed, and the patient should place the next patch on schedule . If the patch is off for 
more than 24 hours or the patie nt is more than 2 days late in changing it, a backup con-
traceptive method should be used for 7 days . Some concern has been raised that preg-
na ncy risks may be increased in fe ma les over 90 kg. COC efficacy is reduced in obese 
females but is bette r than noted with use of barrier methods a lone. This reduced effi-
cacy is due to inc reased basal metabolic rates, augmented adipose tissue sequestration, 
and increased hepatic metabolism of enzymes found in obesity. 
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19.4 NuvaRing vaginal ring 
NuvaRing is a flexible, transparent, soft vaginal ring made of an ethylene vinyl acetate 
copolymer with two steroid reservoir cores providing a daily release of 15 mg EE and 
120 meg of etonogestrel (desogestrel metabolite). It is placed in the vagina by the ado-
lescent for 3 weeks and then removed for 1 week. Quick Start is possible. If the ring is 
expelled, it is simply cleaned and placed back in the vagina; if the ring is removed for 
more than 3 hours, a backup method of contraception is needed until the ring is back 
in the vagina for 7 days. It is an excellent method of contraception for those who are 
comfortable with their bodies. Adolescents are often reticent to use the ring due to the 
method of insertion and removal. Insertion can be simplified by placing the NuvaRing 
in an empty tampon applicator and using the applicator to insert the ring. The user 
needs to be counseled that the ring does not prevent STDs. Advantages of the ring 
include excellent contraceptive efficacy, easily placed as well as removed, confiden-
tial method, continuous hormone release, and rapid return of ovulation after cessa-
tion of the method. Potential adverse effects include vaginitis, vaginal discomfort, 
foreign body sensation, as well as the common side effects of all COCs as mentioned 
above. 
19.5 POPs 
POPs provide contraception by cervical mucus thickening and endometrial atrophy; 
ovulation is not reliably inhibited, leading to pregnancy rates of 1-3 or more per 
100,000. Progestins used in POPs include 0.35 mg of norethindrone (Micronor®; 
Nor-Q.D®) and 0.075 mg of norgestrel (Ovrette®). POPs are suggested by some clini-
cians for sexually active females with contraindication to estrogen (such as hyperten-
sion or coronary heart disease). Typical adverse effects of POPs include amenorrhea 
and irregular uterine bleeding. POPs should not be used by females with ectopic preg-
nancy history or taking certain medications, such as anticonvulsants, rifampin, and gris-
eofulvin. POPs are not typically recommended for adolescents due to the above 
increased pregnancy risk and the need for an active pill (no placebos) to be taken at 
the same time daily, making compliance difficult for teens. 
19.6 ECs 
The following box lists some of the ECs that have been available (28). The Yuzpe reg-
imen uses combination of EE (1 00 meg) and a progestin and results in significant nausea 
due to the high dose of estrogen (use of antiemetic is recommended), while Pia~ B C().n-
tains levonorgestrel only and thus produces less nausea and has been showtob~~().n1e­
what more effective than the Yuzpe regimen. The expected pregnancy rate from one 
unprotected coital episode is about 8 percent; this is reduced to less than 1 percent 
with some ECs if used within 24 hours of unprotected sex. EC is most effective if 
used within the first 72 hours after unprotected sex or contraception failure but may 
be taken up to 5 days after coitus. If the patient is pregnant while taking ECs, the 
fetus is not harmed. ECs are over-the-counter in many parts of the world. They should 
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not be used as regular contraception. Reasons to use ECs include having sex without. 
protection, slippage, or breaking of a condom; missing two or more OCPs in a row; barrier 
contraceptive dislodgement (such as a diaphragm or cervical cap); IUD dislodgement; 
and being more than 14 weeks from the last Depo-Provera® injection. 
19.7 Injectable contraceptives 
DMPA (Depo-Provera®) is a commonly used injectable contraceptive that inhibits 
ovulation, thins the endometrium, and thickens the cervical mucus. It is most com-
monly used in the intramuscular formulation, but a subcutaneous version has been 
developed which may show promise for self-administration in the future. It is a reli-
able contraceptive if taken on a regular basis at a dose of 150 mg every 12 week. 
A very low pregnancy rate is noted at 0.3 percent. It does not contain estrogen and 
thus can be used for those with contraindications to using estrogen. Bone loss is 
noted in adolescents on this contraceptive - an average of 3.1-5 percent after 
2 years of use. However, several studies have shown significant bone mineral density 
recovery after cessation of DMPA, though it is unclear yet whether DMPA decreases 
peak bone density when used during adolescents. Therefore, DMPA should be used 
wi th ca ution in youth at risk for low bone density, such as those with chronic renal 
disease, anorexia nervosa, and those with limited mobility (29) . Use of Depo-Provera 
often leads to irregular menstrual periods and then amenorrhea. The following box 
provides a partial list of adverse effects. Benefits of this contraceptive include reli able 
contraception, reduced dysmenorrhea, less seizure activity in some females with 
epilepsy, and lower PTS. 
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Other injectable contraceptives that are available are Lunelle® (United States), 
Cyclo-Provera, and Cyclofem (5 mg estradiol cypionate and 25 mg medroxy-
progesterone acetate [MPNE2C]); these combination injectables (containing estrogen 
and progesterone) are given intramuscularly every month (every 28-30 days) and 
have very high contraceptive efficacy. Since it contains estrogen, dysfunctional uter-
ine bleeding and amenorrhea are not as common as noted with Depo-Provera. 
Another injectable product is Mesigyna® (with 50 mg of norethindrone and 5 mg 
of estradiol valerate). 
The etonogestrel-releasing implant (available as lmplanon® in the United States 
since 2006) is a subdermal implant consisting of one 40 mm long, 2 mm diameter 
rod. This rod is made up of a core containing 68 mg of etonogestrel within a rod of ethy-
lene vinyl acetate copolymer covered in a memberane of the same material. This 
implant is inserted subdermally, typically in the region of the bicipital groove, using 
the sterile preloaded inserter. lmplanon provides 3 years of contraception by releasing 
a steady dose of progestin causing inhibition of ovulation and increasing cervical 
mucus viscosity. As a progestin-only method of contraception, the implant does not 
have the side effects or contra indications associated with estrogen containing methods. 
Unlike MPA, the implant does not cause decreased levels of estrogen and thus does not 
decrease bone density. 
The benefits include high efficacy, long-acting, non-estrogen-containing, cost effec-
tive, requires little effort of the part of the patient, rapid return to fertility, and the 
benefits of other progestin-only methods. Adverse affects include irregular bleeding, 
headaches, acne, weight gain, possible mood disturbance, and increased blood pres-
sure. If irregular bleeding occurs, the patient should be evaluated for other causes. If 
no other cause is found and the bleeding is significant or disruptive for the patient, non-
steroidal anti-inflammatory drugs, COCs (varying regimens), or EE have been shown 
to be effective to treat breakthrough bleeding due to the implant and possibly other 
progestin-only methods as well. 
The effect of lmplanon may be decreased in those with I iver disease and by medications 
that induce CYP3A, such as many antiepileptics, rifampin, and Saint-John's-wort. Like 
DMPA, many women eventually experience amenorrhea with the implant. Barriers to 
use include cost and the need for insertion and removal. The need for removal by a trained 
professional may also be seen as a benefit in the adolescent population as this gives the 
practitioner an opportunity to counsel the patient on family planning, safer sex practices, 
and additional contraception options as well as to conduct appropriate screening prior to 
the adolescent discontinuing this method, which may decrease unintended pregnancy. 
Overall, implantable contraception is an excellent option for teens. 
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19.8 IUD 
A number of IUDs are available in the world; the three types available in the United 
States are Progestasert IUD®, the ParaGard® (Copper T380A), and the Mirena® 
IUD. The following box lists the contraceptive mechanisms of IUDs. 
Progestasert IUD® is replaced annually and has an expulsion rate of 2.7 percent, 
while ParaGard® is replaced every 8 to 10 years and has an expulsion rate of 5 percent. 
In the United States, concern has been raised about a possible link between its use and 
PID in females due to often criticized research dating to the 1980s. Though controver-
sial, it has limited the use of IUDs in adolescents in the United States; it is used by 
12 percent of contraceptive-using women throughout the world. Data on the currently 
available IUDs show no increase in risk of PID unless the patient has an infection with 
Chlamydia or gonorrhea at the time of placement. Therefore, patients should be 
screened for sexually transmitted infections (STis) prior to IUD placement. 
Mirena IUD (Levonorgestrel-containing IUD; LNG-IUD) is a second-generation of ster-
oid-releasing IUDs. It releases 20 meg of levonorgestrel per 24 hours over the first 5 years 
of use, decreasing to 10 meg per day after 5 years. It is a popular IUD used by more than 
2 million women in the world. It has a failure rate of 0.2 percent in the first year and 0.7 
percent at 5 years. It exerts a local effect on the endometrium as well as the cervical 
mucus; ovulation may continue, and endometrial thinning can lead to amenorrhea. 
The following box lists potential adverse effects of Mirena IUD, the most common of 
which is irregular bleeding. It has been used to reduced menstrual bleeding in females 
with dysfunctional uterine ble-eding because it can reduced menstrual blood loss by 
90 percent. Contraindications to Mirena IUD use include distorted uterine cavity, history 
of subacute bacterial endocarditis, prosthetic heart valves, and active PID. 
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ParaGard® (Copper T380A) is a copper T IUD which prevents pregnancy by the 
interference of sperm motility by the copper ions. ParaGard® is highly effective with 
a first year failure rate of 0.8 percent with typical usage and a high rate of continuation 
among adolescents. The primary benefit to ParaGard® is that it is nonhormonal and 
can therefore be used as reliable contraception in those with contraindications to hor-
mone use or history of side effects with hormonal contraception or those patients 
wishing to avoid hormone usage for other reasons. Adverse effects are primarily in-
creased dysmenorrhea and menstrual bleeding, abdominal pain, expulsion, and rarely 
perforation . Contraindications are similar to those for Mirena. In general, IUDs are a 
safe, effective, long-term method of birth control that can be used in nulliparous ado-
lescents. While not recommended for teens at high risk for STis, IUDs have not been 
found to increase r,isk of PID, nor have they been found to affect future fertility. 
19.9 Barrier methods 
19.9.1 Diaphragm and vaginal spermicides 
The following box, "Vaginal Barrier Contraceptives/' lists barrier contraceptives. These 
methods are only recommended for highly motivated sexually active individuals. 
Clinicians can learn to fit diaphragms, helping determine the proper size, and teaching 
the youth successful use of this method. The diaphragm is used with vaginal cream or 
foam and is often used with the condom. Vaginal contraceptives or spermicides 
include foams, jellies, creams, suppositories, and a contraceptive film. Contraindica-
tions to diaphragm use are listed in the following box, "Contraindications to Use of 
the Diaphragm," and advantages of vaginal contraceptives are listed in the box, "Va-
ginal Contraceptive Advantages." Side effects include vaginal odor and, in rare cases, 
allergic reactions. Females who have diabetes mellitus and use a diaphragm have in-
creased risks for urinary tract infections. In rare cases, toxic shock syndrome may 
occur, and the diaphragm is contraindicated in a female having a history of toxic 
shock syndrome. 
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19.9.2 Cervical cap 
The Prentif® cavity-rim cervica l cap is a small , latex cap (with spermicide placed 
inside) that is half the size of a diaphragm and fits around the cervix via suction. 
Four cervica l sizes are available and about one-fourth of females cannot be f itted 
with a cervical cap. The clinician should obtain cervical cytology before and at the 
time of cervical cap fitting because cervical dysplasia has been reported in cap 
users; additional cervica l cytology is also recommended 3 months after the fitting. Con-
traindications to cap use include cervical laceration, cervical scarring, and a history of 
toxic shock syndrome. 
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19.9.3 Vaginal contraceptive sponge 
The sponge is made of polyurethane with a concave shape; it is a disposable method 
available without prescription, inserted in the vagina up to 2 days before sex and left 
in place 6 to 24 hours after coitus. Adverse effects include vulvar rash, vaginal odor, 
pruritus, candidiasis, and increased risk for urinary tract infection as well as toxic 
shock syndrome. Its contraceptive efficacy is similar to other barrier contraceptives. 
19.9.4 Female condom 
The female condom is a polyurethane bag or sheath that does not require a prescrip-
tion. It is placed in the vagina prior to coitus; it is not used with a male condom. 
Some STD protection is provided by the female condom, and its overall contraceptive 
efficacy is similar to that of other barrier contraceptives- acceptable, but not as good as 
oral contraceptives. 
19.9.5 Male condom 
Male condoms are recommended to reduce the risk for STDs as well as pregnancy. 
Their contraceptive efficacy is similar to other barrier methods. They must be used 
correctly with each act of coitus or their efficacy becomes considerably reduced. 
Latex condoms are associated with increased breakage rates when exposed to high 
temperatures and/or ultraviolet light; they are also weakened by exposure to oil-
based lubricants. Latex allergy is noted in 7 percent of the general population, and 
the polyurethane condom can then be used. In general, male condom usage should 
be encouraged in the adolescent population primarily for STI prevention. However, 
barrier methods are typically not recommended as the sole method of birth control 
in adolescents. 
19.10 Summary 
Contraception is an important concept for sexually active youth who wish to avoid un-
wanted, unplanned pregnancy. This chapter has reviewed effective methods of con-
traption that are available. Clinicians caring for adolescents should ask about the 
sexual behavior of these youth and provide advice on contraception, beginning with 
abstinence. Sexual responsibility involves prevention of unwanted pregnancy, prema-
ture childbearing, and STis. A summary of contraceptive options for sexually active 
adolescent females having chronic illness is provided in ~Tab. 19.5. 
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Tab. 19.5: Chronic Disorders and Contraception (9, 1 0,20,21,22) 
Disorder Recommended Concerns Additional Comments 
Methods 
Anti phospholipid DMPA or the Mirena See increased risks for Risk of thrombosis is 
antibody (aPI) IUD/ intrauterine thombosis in these espec ially increased 
syndrome system (IUS) patients and thus avoid if other risk factors for 
COCs. Avoid COCs in thrombosis are 
these patients with present. 
moderate or high titers 
of antiphospholipid 
antibodies (i.e. at or 
over 40 GPL or MPL 
units). 
Cancer Potentially all COCs are COCs may reduce 
methods; see various contrai ndicated in risks for ovarian and 
cautions. For example: those with breast endometria l 
Avoid DMPA if taking cancer.Progestin and carc inoma. 
chemotherapy due to estrogen receptors are Pregnancy worsens 
increased risks for noted in ovarian cancer breast cancer, 
infection from tissue; thus, COCs are endometrial cancer, 
neutropenia or an not prescribed to ovarian cancer, 
injection-induced patients with ovarian malignant gestational 
hematoma due to cancer. Avoid the trophoblastic disease, 
thrombocytopenia minipill with a positive malignant l iver 
(TCP). Chemotherapy- history for ectopic tumors (hepatoma), 
induced bone loss may pregnancy or if taking and hepatocellular 
be increased by meds with drug liver carcinoma (22). 
DMPA. Avoid IUDs for interactions (i.e. certain 
those with neutropenia anticonvu lsants, 
or TCP. Caution with griseofulvin, rifampin). 
contraceptive implants 
for those with TCP and 
irregular menstrual 
bleeding. 
(Continued) 
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Tab. 19.5: Chronic Disorders and Contraception (9, 10,20,21 ,22) (Continued) 
Disorder Recommended Concerns Addi tional Comments 
Methods 
Congenital heart DMPA and minipill are Those on COCs have Females with valvular 
disease (CHD) recommended for increased risk for heart disease and 
those with CHD if thrombophlebitis, other CHD may be at 
stable. Mirena IUD/ vascular thromboses endocard itis risk 
IUS is usuall y OK. (arterial or venous), and during IUD 
Observe for potential pulmonary embolism. placement and 1 
adverse reactions Avoid COCs (including month after the 
during IUD placement, patch) with a positive placement. 
such as syncope, history for these Pregnancy is 
bradycardia, and conditions. See the associated with 
seizures. Avoid IUD if text. increased adverse 
patient is on Avoid COCs if there is health effects in 
anticoagulation due to increased risk for ischemic heart 
increased risk for thromboembolism or disease, complicated 
bleeding with IUD endocarditis - valvular heart 
placement. depending on the type disease, peripartum 
of CHD. COCs cardiomyopathy, 
(including the patch) stroke (22) . 
are avoided in those 
with CHD with cardiac 
shunts, congestive 
heart disease, low 
output cardiac 
disorders, and coronary 
heart disease. Avoid 
COCs (including patch) 
in those with CHD and 
pul monary 
hypertension. 
Diabetes All methods are Avoid COCs should be COCs do not worsen 
acceptable if the avo ided in any the metaboli c status. 
metabolic status is ado lescent female with Newer oral 
stable: COCs, DMPA, two diabetic contraceptive 
minipill, IUDs. com pi ications progestins 
(peripheral vascular (norgestimate, 
disease, nephropathy, gestodene, and 
and retinopathy), desogestrel) may 
vascular sequelae (i.e. cause less 
VT), or hypertension. carbohydrate 
DMPA is safe even with metabo lism effects 
the presence of than the older 
diabetes complications. progestins. 
IUDs may induce Pregnancy is 
chronic or resistant associated w ith 
(Continued) 
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Tab. 19.5: Chronic Disorders and Contraception (9, 10,20,21 ,22) (Continued) 
Disorder Recommended Concerns Additi onal Comments 
Methods 
Candidaa/bicans increased adverse 
vaginitis in some. health effects in 
insulin-dependant 
diabetes mellitus with 
complications (22). 
Epilepsy DMPA, IUD (Mirena Caution with COCs Avoid minipill due to 
and copper), minipill, since there can be increased risk for 
barrier contraception interference with some pregnancy and 
antiepileptic drugs with potential 
increased pregnancy teratogenici ty of 
risks: carbamazepine antiepil epti c 
(Tegretol) medications. 
Phenobarbital Pregnancy is 
Phenytoin (Dilantin) associated w ith 
Primidone (Mysoline) increased adverse 
Topiramate (mild he a I th effects in 
inducer) (Topamax) epilepsy (22). 
Hyperlipidemia All methods are Avoid COCs if low Research notes that 
recommended for density lipoproteins estrogen can lower 
stable hyperlipidemia. (LDL) level is over 160 high density 
Use low-dose COCs. mgldl, trigl ycerides are lipoprote in levels, 
over 250 mg!dl, or in raise LDL levels, and 
situations with the increase triglyceride 
existence of multiple levels. 
risk factors for coronary 
artery disease (CAD): 
diabetes mellitus, 
hypertension, obesity, 
smoking, and positive 
family history for 
premature CAD. 
Hypertension All methods are used if Avo id estrogen- COCs result in a 
the cond ition is stable. containing methods for small increase in 
unstable hypertension blood pressure -
(such as blood higher increase in 
pressures over 1 60/1 00 anecdotal situations. 
mm Hg). Pregnancy is 
associated with 
increased adverse 
health effects in 
uncontrolled 
hypertension (22). 
Inflammatory bowel All methods are COCs may reduce DMPA may reduce 
sisease (lBO) usually acceptable. bowel symptoms in breakthrough 
(Continued) 
19.11 Internet sites I 381 
Tab. 19.5: Chronic Disorders and Contraception (9, 10,20,21 ,22) (Continued) 
Disorder Recommended Concerns Additional Comments 
Methods 
Avoid DMPA on a active colitis; COCs bleeding and 
prolonged basis in efficacy may be secondary anemia; 
those on cortico- lowered due to may be best for 
steroids due to bone increased breakthrough combination of IBD 
loss exacerbation. bleeding and reduced and coagulation 
OC absorption. Use the disorders. 
patch if gastrointestinal 
absorption may be a 
problem. Mirena IUD/ 
IUS appears to be 
effective and safe. 
Intellectual disabi I ity See schizophrenia 
Liver disease DMPA and IUDs are Avoid COCs in those Incidence of hepatic 
safe with active liver with active liver cell adenoma is 3.4/ 
disease. Barrier disease (including 100,000 pill users. 
contraception is also hepatitis and cirrhosis). Pregnancy is 
fine (except for the COCs are OK when the associated with 
increased pregnancy I iver function tests increased adverse 
risks inherent in this return to normal. health effects in 
method). Unknown the effect of severe 
obesity-induced (decompensated) 
nona! coho! ic cirrhosis (22). 
steatohepatitis on COC 
efficacy. 
Migraine headaches DMPA, the minipill Females with migraine Use COCs with 
(progesterone-only headaches with caution in those with 
pill), and the Mirena complicated migraines migraines and stop if 
IUD in addition to (i.e. with neurological auras develop and/or 
barrier contraceptives symptoms) have the headaches 
heightened risk for become worse. 
cerebral ischemia and 
cerebrovascular 
accidents if placed on 
COCs because of 
estrogen effects 
Obesity Levonorgestrel IUD COCs are good COC efficacy is 
and minipills may be management choices reduced in obese 
the best option for the for obese youth females but is better 
morbidly obese needing contraception than noted with use 
adolescents. COCs or as well as PCOS, of barrier methods 
intravaginal ring are hirsutism, and acne alone. The reduced 
recommended unless vulgaris. efficacy is due to 
estrogen- DMPA may induce increased basal 
(Continued) 
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Tab. 19.5: Chronic D isorders and Contraception (9, 10,20,21 ,22) (Continued) 
Disorder Recommended Concerns Add itional Comments 
Methods 
contraindications arise weight ga in, and this metabolic rates, 
(as thrombo- should be closely augmented adipose 
embolism, others). monitored. tissue sequestration, 
and increased hepatic 
metabolism of 
enzymes. 
Pulmonary disease All methods are COCs are safe and Can use all methods 
acceptable in patients effective in those with in those with asthma. 
with cystic fibrosis (CF) CF. Bronchial mucus is If pulmonary 
with no other not thickened to a tuberculosis is 
contraindications for major extent (as with present, ri fampin can 
contracept ives. cervi ca l mucus) to decrease COC 
interfere with efficacy. 
contraception. 
Pulmonary emboli sm 
(PE) is a rare event-
avoid COCs if other 
high risk factors for PE 
are present in CF 
females . 
Renal disease If the renal disease COCs are safe for ESRD COCs may improve 
(i ncl udi ng end-stage if renal state is not hyper- menorrhea in 
renal disease, or ESRD) impaired (stable) with some with ESRD. 
is stable, OK to use no hypertension, 
COCs, DMPA, Mirena cardiovascular disease, 
IUD/IUS, and barrier and thromboembolism. 
contraception. Estrogen is 
contraind icated in 
those with ESRD with 
significant 
hypertension or if 
bedridden. 
Avoid DMPA if bone 
loss is of concern. 
Avoid the IUD with 
increased risk of 
endometritis and 
worsening anemia. 
Rheumatoid arthritis COCs, Depo-Provera, Potential concern w ith Avoid COCs if there 
(RA) barriers IUDs due to potential is increased risk for 
infection. vasculitis, 
Females w ith severe RA atherosclerosis, or 
may have difficulty ischemia. See 
inserting a vaginal ring, possible drug 
(Continued) 
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Tab. 19.5: Chronic Disorders and Contraception (9,1 0,20,21,22) (Continued) 
Disorder Recommended Concerns Additional Comments 
Methods 
diaphragm, cervical interactions between 
cap, or other barrier COCs and RA drugs, 
contraceptives. such as warfarin, 
corticosteroids 
cyclosporine, and 
some anticonvul-
sants. 
Sickle-cell disorders COCs, Depo-Provera, Pregnancy increases Sickling is a different 
barriers risk for both mother process than 
and fetus. COCs do not thrombosis, and thus 
increased risk due to COCs do not increase 
sickling; Depo-Provera risk for thombosis. 
may reduce sickling 
crises. Pregnancy is 
associated with 
increased adverse 
health effects in sickle-
cell disease (22). 
Systemic lupus COCs may be the best Avoid COCs in the DMPA may worsen 
erythematosus (SLE) choice. presence of vasculitis, bone loss already 
nephritis, or the aPI present in SLE 
syndrome. Avoid the patients. Avoid the 
progesterone IUD due to the 
drospirenone if renal lowered immune 
failure noted since status of SLE patients. 
hyperka lemia can 
develop. Pregnancy is 
associated with 
increased adverse 
health effects in SLE 
(22). 
Thyroid disease All methods are No contrai ndications If she is on 
acceptable. for contracept ion w ith levothyroxine, check 
hyper-/hypothyroidism . T 4 and TSH leve ls 
after two oral 
contraceptive cycles. 
Schizophrenia DMPA and IUDs Some females find it Sterili zation remains 
difficult to use COCs or a complex and highly 
use barriers due to controversial concept 
limited mental health in contemporary 
status. society. 
Miscellaneous HIV: DMPA works HIV: Potential drug HIV: Use condoms as 
well. Alternative: IUD. interactions between well to protect 
(Con tin ued) 
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Tab. 19.5: Chronic Disorders and Contraception (9, 10,20,21 ,22) (Continued) 
Disorder Recommended 
Methods 
Concerns 
COCs and certain anti-
HIV drugs; some cause 
decrease in estrogen 
(lopinavir/ ritonavir and 
nevirapine), and some 
cause an increase in 
estrogen (atazanavir 
and efavirenz). 
Additional Comments 
partner from HIV 
transmission. 
Pregnancy is 
associated with 
increased adverse 
health effects in HIV/ 
AIDs (22). 
GPL, lgG phospholipid; MPL, micrograms of lgM antibodies; TSH, thyroid-stimulating hormone 
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